Michele Hu is Associate Professor in the Department of Clinical Neurology at the Nuffield Department of Clinical Neurosciences, University of Oxford and Consultant Neurologist at Oxford University Hospitals. After obtaining her medical degree from the University of London in 1993, Michele’s interest in Parkinson’s disease started in 1998 when she was awarded an Action Research Training Fellowship to study brain function in Parkinson’s disease patients using MRI and PET brain imaging techniques. In 2001 she was awarded her PhD based on this work, and went on to train in Parkinson’s disease and movement disorders at the National Hospital for Neurology and Neurosurgery, Royal Free Hospital and King’s College Hospital, London.
Since commencing her consultant appointment in 2005, Michele has set up a clinical Parkinson’s disease, atypical parkinsonism and movement disorders service in the John Radcliffe Hospital, Oxford University Hospitals NHS Trust. She is an appointed member of the Parkinson’s Disease Clinical Study Group and Parkinson’s Portfolio Management Group of the National Dementias and Neurodegenerative Disorders Network (DeNDRoN) and is NIHR Thames Valley and South Midlands Research Director for Parkinson’s disease. She also chairs the Research Engagement sub-committee of the UK Parkinson's Excellence Network, formed in 2015.
Awards, Training and Qualifications
- MBBS University of London 1993
- PhD University of London 2001
- FRCP Royal College of Physicians, London 2009
Sources of Funding
- Parkinson's UK Monument Discovery Award to the Oxford Parkinson's Disease Centre (OPDC), 2010-2020 (£10.8 Million total)
- Oxford Biomedical Research Centre (BRC) Functional Neuroscience and Neuroimaging Theme
- NIHR Clinical Research Network: Thames Valley and South Midlands
- Innovative Medicines Initiative. “StemBANCC. Stem cells for Biological Assays of Novel drugs and prediCtive toxicology”
- Parkinson’s UK Innovation Grant “Predicting risk of dyskinesia in Parkinson’s disease”
- Parkinson’s UK Translational Research Grant. ‘Point of care PD diagnosis and prognosis’
- ”Virtual, physiological and computational neuromuscular models for the predictive treatment of Parkinson’s Disease- NoTremor”. EU small or medium-scale focused research project (STREP) Award
- Oxford/UCB Alliance. "Novel biomarkers to understand the earliest pathological pathways in Parkinson’s disease".
“Biomarkers for Dementia and Cognitive decline in Parkinson’s disease”, Parkinson’s UK innovation grant.
“Harmonization of biomarker assessment in longitudinal cohort studies in Parkinson’s disease”, JPND research programme grant: EU Joint Programme- Neurodegenerative Disease Research.
“Development of potential diagnostic biomarkers in Parkinson’s disease”, Michael J. Fox Foundation Biomarker Grant.
MBBS FRCP PhD
Associate Professor and Consultant Neurologist
- Oxford Movement Disorders Group Research Group
‘Understanding the early pathological pathways to Parkinson’s disease’, Parkinson’s UK Monument Discovery Award, awarded September 2009 and 2014.PI- Professor Richard Wade-Martins, co-PI Dr Michele Hu.
The Oxford Parkinson’s Disease Centre applied for this £5.0 million Discovery Award among national competition in July 2009, with a successful £5.8 million renewal funding application awarded in 2014.This multi-disciplinary project brings together scientists from Oxford University with international expertise in genomics; the development, analysis and utilisation of animal models using the tools of molecular genetics, neuropathology and neuropharmacology; and the analysis of biomarkers including a proteomics study and novel MRI paradigms in a large clinical cohort of 1500 people with Parkinson’s disease.
Dr Michele Hu leads the clinical theme in establishing a cohort of early Parkinson’s disease patients recruited from a population base across the Thames Valley, and followed longitudinally over 10 years to develop and validate early PD biomarkers. So far, in excess of 1500 participants in total, who comprise Parkinson's and control subjects, Parkinson's siblings and individuals with REM sleep behaviour disorder, have been recruited to this study. Her current funding facilitates translational research in the field of longitudinal cohort studies and biomarkers of early pre-motor and motor Parkinson’s disease.
Other Research Activities
Dr Michele Hu is currently working with Dr Chrystalina Antoniades and Professor Chris Kennard at the Nuffield Department of Clinical Neurosciences, Oxford University to pilot and develop eye movement saccadometry and hand tapping measurements in early and premotor Parkinson’s patients. She is research director for Parkinson’s disease in the Thames Valley Dementias and Neurodegenerative Disease Research Network (DeNDRoN) and a member of the national DeNDRoN Parkinson’s Clinical Study Group, which aims to promote high quality research in neurodegenerative disorders. She chairs the Research Engagement sub-committee of the UK Parkinson's Excellence Network, formed in 2015 to promote universal standards of excellence of care for Parkinson's individuals.
Basal ganglia dysfunction in idiopathic REM sleep behaviour disorder parallels that in early Parkinson's disease.
Rolinski M. et al, (2016), Brain, 139, 2224 - 2234
Visual short-term memory deficits in REM sleep behaviour disorder mirror those in Parkinson's disease.
Rolinski M. et al, (2016), Brain, 139, 47 - 53
Functional connectivity in the basal ganglia network differentiates PD patients from controls.
Szewczyk-Krolikowski K. et al, (2014), Neurology, 83, 208 - 214
Predictors of cognitive impairment in an early stage Parkinson's disease cohort.
Hu MT. et al, (2014), Mov Disord, 29, 351 - 359
REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson's disease.
Rolinski M. et al, (2014), J Neurol Neurosurg Psychiatry, 85, 560 - 566
Prodromal Parkinsonism and neurodegenerative risk stratification in REM sleep behaviour disorder.
Barber TR. et al, (2017), Sleep
Personality and addictive behaviours in early Parkinson's disease and REM sleep behaviour disorder.
Baig F. et al, (2017), Parkinsonism Relat Disord, 37, 72 - 78
Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson's disease.
Sandor C. et al, (2017), Hum Mol Genet, 26, 552 - 566
Discovery and functional prioritization of Parkinson's disease candidate genes from large-scale whole exome sequencing
Jansen IE. et al, (2017), Genome Biology, 18
Whole-exome sequencing of 228 patients with sporadic Parkinson's disease.
Sandor C. et al, (2017), Sci Rep, 7